Genetic changes in the genesis of gastrointestinal carcinoma.

Endoscopy

Institute of Human Genetics, University Hospital, Homburg, Germany.

Published: November 1992

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2007-1010583DOI Listing

Publication Analysis

Top Keywords

genetic changes
4
changes genesis
4
genesis gastrointestinal
4
gastrointestinal carcinoma
4
genetic
1
genesis
1
gastrointestinal
1
carcinoma
1

Similar Publications

Gastrointestinal (GI) symptoms occur frequently in pregnant women, resulting in poor quality of life. These patients frequently require co-management with the obstetrician and a physician/GI specialist. The causation is complex and multifactorial.

View Article and Find Full Text PDF

The choice of organism to host a genetic circuit, the chassis, is often defaulted to model organisms due to their amenability. The chassis-design space has therefore remained underexplored as an engineering variable. In this work, we explored the design space of a genetic toggle switch through variations in nine ribosome binding site compositions and three host contexts, creating 27 circuit variants.

View Article and Find Full Text PDF

Xanthine nucleosides play a significant role in the expansion of the four-letter genetic code. Herein, 7-functionalized 8-aza-7-deazaxanthine ribo- and 2'-deoxyribonucleosides are described. 2-Amino-6-alkoxy nucleosides were converted to halogenated 8-aza-7-deazaxanthine nucleosides by deamination followed by hydroxy/alkoxy substitution.

View Article and Find Full Text PDF

Objective: Around 30% of people with schizophrenia are refractory to antipsychotic treatment (treatment-resistant schizophrenia). Abnormal structural neuroimaging findings, in particular volume and thickness reductions, are often described in schizophrenia. Novel biomarkers of active brain pathology such as neurofilament light chain protein are now expected to improve current understanding of psychiatric disorders, including schizophrenia.

View Article and Find Full Text PDF

Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.

Am J Med Genet C Semin Med Genet

January 2025

Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!